# | ||||
---|---|---|---|---|
1 | NANOTAM Development and Evaluation of Nanomedicines for Cancer Treatment through Immunomodulation: Targeting Tumor-Associated Macrophages | 2015 | 168˙277.00 | 168˙277.00 |
2 | PHII PTX3 in Humoral Innate Immunity | 2015 | 2˙497˙081.00 | 2˙497˙081.00 |
3 | PERSYST Generation and maintenance of long-lived memory T cells in humans | 2015 | 1˙500˙000.00 | 1˙500˙000.00 |
4 | MIRCAP Innovative nanoparticle formulation for a miR-133 based treatment of cardiac hypertrophy | 2016 | 150˙000.00 | 150˙000.00 |
5 | MONONANOCHEM In vivo engineering of monocytes loaded with nano-chemotherapeutic formulations: a novel live-cell mediated drug delivery system for the treatment of cancer | 2017 | 168˙277.00 | 168˙277.00 |
6 | TUDCA-ALS Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS) | 2018 | 5˙596˙928.00 | 5˙596˙928.00 |
7 | SUMO-PCDH10 Physiological consequences of Protocadherin-10 sumoylation on neuronal function. | 2019 | 171˙473.00 | 171˙473.00 |
8 | DAPHNIS Role of the Maternal Gut Microbiota in Immune Activation at the Maternal-Foetal Interface: Impact on Preeclampsia and Offspring's Immune Development | 2019 | 168˙277.00 | 168˙277.00 |
9 | PITUITARY ENHANCERS Identification and functional validation of novel enhancer sequences involved in pituitary gland development and pathology | 2020 | 183˙473.00 | 183˙473.00 |
The Institution HUMANITAS MIRASOLE SPA has been involved also in the following Horizon 2020 projects.